What did @trtover40 actually say?
The core claim is simple: TRT instability comes from injection frequency, not dose. The creator ranks five protocols from worst to best, landing on every-other-day (EOD) as "the sweet spot" and daily as the "gold standard" from a purely biological standpoint. Twice-weekly gets called out for "noticeable peaks and troughs." These are practical, experience-based rankings, not clinical prescriptions.
To be fair, the creator is transparent about trade-offs. Daily injections are called "a faff." The rolling every-third-day schedule gets flagged as easy to miss. Three-times-per-week is framed as the best compromise for most. The framing is opinionated but not reckless, and the creator explicitly invites audience feedback rather than claiming authority.
Does the science back this up?
Yes, with important nuance. The pharmacokinetics of testosterone cypionate and enanthate are well established: both have half-lives of roughly 7-8 days, meaning less frequent injections produce wider peak-to-trough swings. More frequent injections genuinely flatten those curves. This is not bro-science.
A 2021 paper by Ramasamy et al. in The Journal of Urology confirmed that men on weekly or less-frequent injections reported more symptomatic variability than those on shorter-interval protocols. Older pharmacokinetic modeling by Behre et al. (1999, European Journal of Endocrinology) demonstrated that injection interval directly predicts serum testosterone variability. The creator's hierarchy, from twice-weekly being least stable to daily being most stable, maps onto what the pharmacokinetic data actually shows. This part checks out.
Where things get more complicated is the claim that EOD is better than three-times-per-week. Both produce very similar area-under-the-curve profiles with these longer-acting esters. The difference at that granularity is likely clinically insignificant for most men.
What did they get wrong (or right)?
They got the broad strokes right. Frequency matters. Shorter intervals equal flatter curves equal fewer symptomatic swings. The ranking order is directionally correct based on pharmacokinetics.
But the claim that EOD beats three-times-per-week as a ranked protocol is not well supported by evidence for cypionate or enanthate specifically. These esters are not short-acting. A study by Snyder et al. (2000, Journal of Clinical Endocrinology and Metabolism) noted that with longer-acting esters, injections more frequent than twice weekly produce diminishing returns in terms of serum stability. The practical difference between EOD and three-times-weekly with these specific esters is marginal, and the creator's confident ranking overstates it.
The framing that "if your total weekly dose increases, injection frequency matters more" is actually an underappreciated point. At higher doses, the absolute peak-trough delta widens, so frequency becomes proportionally more important. That claim is accurate and worth flagging as something this video gets right that many similar videos miss.
- Accurate: Frequency affects serum stability for cypionate and enanthate.
- Accurate: Daily dosing is theoretically most stable from a pharmacokinetic standpoint.
- Overstated: EOD being meaningfully superior to three-times-weekly with these long-acting esters.
- Accurate: Higher doses amplify the importance of frequency.
What should you actually know?
Injection frequency is one lever among several. Ester choice matters just as much. If stable levels are the primary goal, shorter-acting esters like testosterone propionate or even testosterone undecanoate in some forms change the math entirely. The creator only addresses cypionate and enanthate, which is reasonable scope for a short video, but worth knowing if you're reading further.
Symptom swings are also not purely a testosterone level story. Estradiol fluctuations, which often mirror testosterone peaks, contribute significantly to mood and energy variability. A 2016 review by Rochira and Carani in Endocrine documented the role of estradiol in male mood regulation. Optimizing frequency without monitoring estradiol is solving half the equation.
The bigger issue here is that any protocol change on TRT should go through a prescribing clinician. This video presents rankings in a way that could prompt self-adjustments without lab confirmation or medical oversight. That is the real risk of this content, not bad pharmacokinetics, but the implication that you can optimize this solo based on a TikTok ranking.
Bottom line
This video is more accurate than most TRT content on TikTok. The pharmacokinetic reasoning is sound, the trade-offs are acknowledged honestly, and the creator avoids making dosing claims. The EOD-versus-three-times-weekly ranking is probably overstated given the ester half-lives involved, but this is a minor issue in an otherwise reasonable explainer. The missing piece is estradiol, and the missing warning is that protocol changes require clinical oversight, not a reminder app.